Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Zr- BI 765063

Phase 1Small molecule

Boehringer Ingelheim

Zr- BI 765063 is one of 31 small molecule programs targeting Melanoma. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

30

Competitors

Pipeline

Status by Indication[3][1]

Indication

MelanomaActive, not recruiting

MelanomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Nexavar

KIMMTRAK

IImmunocore Ltd

Interferon Alfa

Relatlimab+nivolumab

Bristol-Myers Squibb

Zelboraf

CConrado Roberto Hoffmann Filho

Intron a

Opdualag

Bristol-Myers Squibb

PEG-Intron

Talimogene Laherparepvec

Tuoyi

CCoherus Oncology, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Melanoma1 trial

An Open Label Phase I PET Imaging Study to Investigate the Bio-distribution and Tumor Uptake of [89Zr]Zr-BI 765063 and [89Zr]Zr-BI 770371 in Patients With Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer or Melanoma Who Are Treated With Ezabenlimab

Active, not recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05068102·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zr- BI 765063. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zr- BI 765063 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zr- BI 765063. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Boehringer Ingelheim

Related News